Emory Pituitary Center

The Emory Pituitary Center offers a multidisciplinary approach to care with a team of pituitary specialists world-renowned for their expertise in the treatment of pituitary adenomas (tumors) and other conditions associated with the pituitary gland. The center provides state-of-the-art diagnostic services in all aspects of endocrinology and neuroradiology and comprehensive therapy for pituitary and hypothalamic disorders, with specialization in neurosurgery, radiation and medical therapy.

Co-directors of the Emory Pituitary Center Nelson Oyesiku, MD, PhD, FACS and Adriana Ioachimescu, MD, PhD partner with a team of specialists who collaborate in the diagnosis, treatment and care of patients with pituitary tumors. In conjunction with the Department of Radiation Therapy, Dr. Oyesiku also offers stereostactic radiosurgery for patients with pituitary lesions. His Laboratory of Molecular Neurosurgery and Biotechnology is a leading center for research in the molecular biology of pituitary tumors.

Experience and Expertise

Nelson Oyesiku, MD, PhD, FACS, has performed over 2,000 pituitary adenoma surgeries. To put this in perspective, most medical centers have performed approximately 300. Emory Pituitary Center also has a tumor bank containing over 600 pituitary specimens and catalogued information about the different types of pituitary disorders.  

Coordinated Care

We understand many pituitary patients have spent years treating symptoms and not the pituitary disorder. In many medical centers, a patient may have to wait weeks between seeing an endocrinologist and a pituitary surgeon or another specialist. Here at Emory, a patient often can see all of the necessary specialists in one visit, when appropriate.


Emory is one of only four centers in the nation that performs 3-D endoscopic surgical removal of pituitary tumors. The 3-D endoscope offers the ability to see the tumor three-dimensionally, thus enabling the surgeon to remove the tumor in its entirety and minimizing the incidence of errors.

Reputation for Excellence

U.S. News & World Report ranked Emory University Hospital as one of America's Best Hospitals for neurology/neurosurgery five years in row.

Clinical Trials

To reach a research coordinator, please call 404-778-7673 or email cushingsresearch@emory.edu

A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease, currently enrolling.

Somatuline Depot (Lanreotide) Injection for Acromegaly: a Post-marketing Observational Study (SODA), multicentric prospective observational study, closed.

Molecular Biology of Pituitary Tumors, currently enrolling.

A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing’s disease, ongoing, closed for enrollment.

An ACromegaly, open-label, multi-Center, Safety monitoring program for treating patients with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS), closed.

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape), multi-center trial, closed.

Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison with Nonfunctioning Pituitary Tumors, closed.

Become a Patient